共查询到20条相似文献,搜索用时 15 毫秒
1.
Gastrectomy for a patient with early gastric cancer and human immunodeficiency virus (HIV) infection
Kazuhiro Yasuda Norio Shiraishi Yosuke Adachi Seigo Kitano Hiroshi Kikuchi Koji Ito Takayuki Noguchi Kenji Kashima 《Gastric cancer》2001,4(1):39-42
Received: December 5, 2000 / Accepted: January 26, 2001 相似文献
2.
3.
BACKGROUND: The objective of this study was to compare the human immunodeficiency virus (HIV) viral load (VL) and CD4 counts in patients infected with HIV with and without cervical cancer. The authors hypothesized that HIV-positive women with cervical cancer would have a greater risk of immune suppression. METHODS: A case-control study was conducted that included all HIV-positive patients who were seen at the authors' institution from January 1, 1995 to April 20, 2006 with invasive cervical cancer (cases) and without invasive cervical cancer (controls). Patients were included only if they had a CD4 count recorded<6 months before or<3 months after their diagnosis of invasive cervical cancer (cases) or at their last gynecologic examination (controls). Controls were matched to cases on a 4:1 ratio according to current smoking history. Patients were considered immunocompetent if they had both a CD4 count>200 cells/microL and a VL<10,000 copies/mL. RESULTS: In total, 15 cases and 60 controls were identified. The median CD4 count for cases was 208 cells/microL (range, 18-1102 cells/microL) compared with 445 cells/microL (range, 20-1201 cells/microL) for controls (P=.03). The median VL was 16,918 copies/mL (range, 50-214,915 copies/mL) for cases compared with 1430 copies/mL (range, 50-571,000 copies/mL) for controls (P=.15). Only 1 of 14 cases (7%) was immunocompetent compared with 35 of 55 controls (64%; odds ratio, 0.04; 95% confidence interval, 0-0.37; P<.001). This significance was maintained after adjusting for other factors (P=.002). CONCLUSIONS: Women with HIV who were diagnosed with invasive cervical cancer appeared to have a much greater degree of immunosuppression than women with HIV without invasive cervical cancer. 相似文献
4.
Goedert JJ Schairer C McNeel TS Hessol NA Rabkin CS Engels EA;HIV/AIDS Cancer Match Study 《British journal of cancer》2006,95(5):642-648
By linking HIV/AIDS and cancer surveillance data in 12 US regions, breast and reproductive cancer risks with AIDS were compared to those in the general population. Trends in standardized incidence ratios (SIRs) were assessed by CD4 count, AIDS-relative time, and calendar time. Standardized incidence ratios were indirectly adjusted for cancer risk factors using data from AIDS cohort participants and the general population. With AIDS, 313 women developed breast cancer (SIR 0.69, 95% confidence interval (CI) 0.62-0.77), 42 developed ovary cancer (SIR 1.05, 95% CI, 0.75-1.42), and 31 developed uterine corpus cancer (SIR 0.57, 95% CI, 0.39-0.81). Uterine cancer risk was reduced significantly after age 50 (SIR 0.33). Breast cancer risk was reduced significantly both before (SIR 0.71) and after (SIR 0.66) age 50, and was lower for local or regional (SIR 0.54) than distant (SIR 0.89) disease. Breast cancer risk varied little by CD4 count (Ptrend=0.47) or AIDS-relative time (Ptrend=0.14) or after adjustment for established cancer risk factors. However, it increased significantly between 1980 and 2002 (Ptrend=0.003), approaching the risk of the general population. We conclude that the cancer deficit reflected direct or indirect effects of HIV/AIDS and that anti-HIV therapy reduced these effects. 相似文献
5.
Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Meredith S. Shiels PhD Glenn Copeland MBA Marc T. Goodman PhD Janna Harrell MS Charles F. Lynch MD PhD Karen Pawlish ScD Ruth M. Pfeiffer PhD Eric A. Engels MD 《Cancer》2015,121(12):2063-2071
6.
Philip E. Castle PhD MPH Mark H. Einstein MD MS Vikrant V. Sahasrabuddhe MBBS MPH DrPH 《CA: a cancer journal for clinicians》2021,71(6):505-526
Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low-income countries, cervical cancer is often the leading cause of cancer-related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome are at a particularly high risk of cervical cancer because of an impaired immune response to human papillomavirus, the obligate cause of virtually all cervical cancers. Globally, approximately 1 in 20 cervical cancers is attributable to HIV; in sub-Saharan Africa, approximately 1 in 5 cervical cancers is due to HIV. Here, the authors provide a critical appraisal of the evidence to date on the impact of HIV disease on cervical cancer risk, describe key methodologic issues, and frame the key outstanding research questions, especially as they apply to ongoing global efforts for prevention and control of cervical cancer. Expanded efforts to integrate HIV care with cervical cancer prevention and control, and vice versa, could assist the global effort to eliminate cervical cancer as a public health problem. 相似文献
7.
Mary Cianfrocca DO Sandra Lee ScD Jamie Von Roenn MD Anil Tulpule MD Bruce J. Dezube MD David M. Aboulafia MD Richard F. Ambinder MD Jeannette Y. Lee PhD Susan E. Krown MD Joseph A. Sparano MD 《Cancer》2010,116(16):3969-3977
BACKGROUND:
Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)‐associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined.METHODS:
Patients with advanced HIV‐associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle.RESULTS:
The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73% of patients received highly active antiretroviral therapy (HAART) and 32% had an undetectable viral load (<400 copies/mL). Treatment was associated with significant improvements in pain (P = .024) and swelling (P < .001). Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved. Of the 41 patients who reported swelling at baseline, 38 (93%) improved. Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P = .49), median progression‐free survival (17.5 months vs 12.2 months; P = .66), and 2‐year survival rates (79% vs 78%; P = .75), but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P = .077).CONCLUSIONS:
Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV‐associated KS treated in the HAART era. Cancer 2010. © 2010 American Cancer Society. 相似文献8.
9.
L. Stewart Massad MD Eric C. Seaberg PhD D. Heather Watts MD Howard Minkoff MD Alexandra M. Levine MD Donna Henry MD MPH Christine Colie MD Teresa M. Darragh MD Nancy A. Hessol MSPH 《Cancer》2009,115(3):524-530
BACKGROUND:
The objective of this study was to estimate the incidence of invasive cervical cancer (ICC) in women with human immunodeficiency virus (HIV) and compare it with the incidence in HIV‐uninfected women.METHODS:
In a cohort study of HIV‐infected and uninfected women who had Papanicolaou tests obtained every 6 months, pathology reports were retrieved for women who had biopsy results or a self‐report of ICC. Histology was reviewed when reports confirmed ICC. Incidence rates were calculated and compared with those in HIV‐negative women.RESULTS:
After a median follow‐up of 10.3 years, 3 ICCs were confirmed in HIV‐seropositive women, and none were confirmed in HIV‐seronegative women. The ICC incidence rate was not found to be associated significantly with HIV status (HIV‐negative women [0 of 100,000 person‐years] vs HIV‐positive women [21.4 of 100,000 person‐years]; P = .59). A calculated incidence rate ratio standardized to expected results from the Surveillance Epidemiology and End Results database that was restricted to HIV‐infected Women's Interagency HIV Study participants was 1.32 (95% confidence interval, 0.27‐3.85; P = 0.80).CONCLUSIONS:
Among women with HIV in a prospective study that incorporated cervical cancer prevention measures, the incidence of ICC was not significantly higher than that in a comparison group of HIV‐negative women. Cancer 2009. Published 2009 by the American Cancer Society. 相似文献10.
11.
Shortly after the onset of the acquired immunodeficiency syndrome (AIDS) epidemic in the 1980s, reports of radiation‐associated toxicity in patients with the human immunodeficiency virus (HIV) and AIDS began to appear in the medical literature. Although the majority of reports have focused on AIDS‐defining malignancies such as Kaposi sarcoma, greater‐than‐expected toxicity after a course of radiotherapy or chemoradiotherapy has also been documented in cancers not generally classified as being related to HIV. With improved antiretroviral therapies, HIV patients are living longer and have the potential to develop a variety of HIV‐associated and nonassociated malignancies that require treatment, including radiotherapy. This review reports the published data regarding the interactions of HIV, AIDS, and antiretroviral therapy with radiotherapy and implications for the management of malignancies in patients with HIV. Cancer 2010. Published 2009 by the American Cancer Society. 相似文献
12.
Engels EA Rodman LH Frisch M Goedert JJ Biggar RJ 《International journal of cancer. Journal international du cancer》2003,106(2):283-287
Persons with acquired immunodeficiency syndrome (AIDS) have increased risk for non-Hodgkin's lymphoma (NHL). Recent studies have reported the detection of DNA sequences from simian virus 40 (SV40), a macaque polyomavirus that contaminated early poliovirus vaccines, in a large proportion of AIDS-associated NHLs. To examine the association between SV40 exposure and NHL risk, we analyzed data from a U.S. registry-based cohort study of persons with AIDS (1980-96). We calculated NHL incidence in persons born in 1958-61 (exposed to SV40-contaminated poliovirus vaccine as children, n = 39,468) and in 1964-67 (born after vaccines were cleared of SV40 and thus unexposed, n = 17,340). Among persons with AIDS, NHL incidence was 11.7 per 1,000 person-years in SV40-exposed individuals (616 NHL cases) and 10.1 per 1,000 person-years in SV40-unexposed individuals (230 cases; unadjusted relative risk 1.15, 95% CI 0.99-1.34, p = 0.06). Because of differences in cohorts' birth years and the evolving demographics of the AIDS epidemic, SV40-exposed subjects were older at AIDS onset than unexposed subjects (mean age 32.0 vs. 27.2 years, p < 0.0001), and the cohorts differed by sex (p < 0.0001) and ethnic group (p < 0.0001). Since NHL incidence was relatively high among whites (p < 0.0001) and homosexual males (p < 0.0001) and increased with age (p = 0.09), comparisons required adjustments for these factors. After adjustment, SV40 exposure was not associated with NHL incidence (adjusted relative risk 0.97, 95% CI 0.79-1.20, p = 0.80). We conclude that childhood exposure to SV40 through receipt of contaminated poliovirus vaccine was not associated with increased risk for AIDS-associated NHL. Our findings do not support a role for SV40 in lymphomagenesis among immunosuppressed persons. 相似文献
13.
Surbhi Grover MD MPH Emily C. MacDuffie BA Qiao Wang MPH Memory Bvochora-Nsingo MD Rohini K. Bhatia BA Dawn Balang MD Sebathu P. Chiyapo MD Rebecca Luckett MD MPH Doreen Ramogola-Masire MD Scott L. Dryden-Peterson MD Lilie L. Lin MD Sanghyuk S. Shin PhD Nicola M. Zetola MD MPH 《Cancer》2019,125(10):1645-1653
14.
15.
BACKGROUND:
Very few published studies have dealt with the management of locally advanced cervix carcinoma among human immunodeficiency virus (HIV)‐positive patients. The objective of this study was to compare the clinical characteristics, radiation and chemotherapy treatments, and outcomes in a cohort of HIV‐positive and HIV‐negative women with cervical cancer.METHODS:
The authors reviewed the charts of 59 HIV‐positive patients and 324 HIV‐negative patients who had stage IB1 to IIIB cervical carcinoma and who received radiation therapy. Demographic and clinical characteristics were compared at the time of diagnosis; and radiation doses, chemotherapy cycles, and responses were compared at the time of brachytherapy and at 6‐week follow‐up. Logistic regression models of response to treatment were developed.RESULTS:
Forty‐nine HIV‐positive patients (88.1%) but only 213 HIV‐negative patients (65.7%) presented with stage IIIB disease (P = .009). Forty‐seven HIV‐positive patients (79.7%) and 291 HIV‐negative patients (89.8%) completed the equivalent dose of 68 Grays (Gy) external‐ beam radiation and high‐dose‐rate brachytherapy. (P = .03). Of the 333 patients who commenced concurrent chemotherapy, 26 HIV‐positive patients (53.1%) and 212 HIV‐negative patients (74.6%) completed ≥4 weekly cycles of platinum‐based treatment. Follow‐up was censured at 6 weeks. In models that included age, disease stage, HIV status, and treatment, a poor response at 6 weeks was associated only with stage IIIB disease (odds ratio, 2.39; 95% confidence interval, 1.45‐3.96) and receiving an equivalent radiation dose in 2‐Gy fractions of <68 Gy (OR, 3.14; 95% CI, 1.24‐7.94).CONCLUSIONS:
HIV‐positive patients fared worse than HIV‐negative patients because of later presentation and a decreased likelihood of completing treatment. The current findings emphasize the importance of completing irradiation therapy. Further studies will address the association of these variables with survival. Cancer 2011. © 2011 American Cancer Society. 相似文献16.
BACKGROUND:
The overall burden of cancer may increase as individuals with acquired immunodeficiency syndrome (AIDS) live longer because of highly active antiretroviral therapy (HAART), which has been widely available since 1996.METHODS:
A population‐based, record‐linkage study identified cancers in 472,378 individuals with AIDS from 1980 to 2006. By using nonparametric competing‐risk methods, the cumulative incidence of cancer was estimated across 3 calendar periods (AIDS onset in 1980‐1989, 1990‐1995, and 1996‐2006).RESULTS:
Measured at 5 years after AIDS onset, the cumulative incidence of AIDS‐defining cancer (ADC) declined sharply across the 3 AIDS calendar periods (from 18% in 1980‐1989, to 11% in 1990‐1995, to 4.2% in 1996‐2006 [ie, the HAART era]). The cumulative incidence of Kaposi sarcoma declined from 14.3% during 1980 to 1989, to 6.7% during 1990 to 1995, and to 1.8% during 1996 to 2006. The cumulative incidence of non‐Hodgkin lymphoma (NHL) declined from 3.8% during 1990 through 1995 to 2.2% during 1996 through 2006; during the HAART era, NHL was the most common ADC (53%). The cumulative incidence of non‐AIDS‐defining cancer (NADC) increased from 1.1% to 1.5% with no change thereafter (1%; 1996‐2006), in part because of declines in competing mortality. However, cumulative incidence increased steadily over time for specific NADCs (anal cancer, Hodgkin lymphoma, and liver cancer). The cumulative incidence of lung cancer increased from 0.14% during 1980 to 1989 to 0.32% during 1990 to 1995, and no change was observed thereafter.CONCLUSIONS:
Dramatically declining cumulative incidence was noted in 2 major ADCs (Kaposi sarcoma and NHL), and increases were observed in some NADCs (specifically, cancers of the anus, liver, and lung and Hodgkin lymphoma). As HIV/AIDS is increasingly managed as a chronic disease, greater attention should be focused on cancer screening and prevention. Cancer 2011. Published 2010 by American Cancer Society. 相似文献17.
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus‐positive patients with cancer: AIDS Malignancy Consortium trial AMC 061
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Michelle A. Rudek PharmD PhD Page C. Moore PhD Ronald T. Mitsuyasu MD Bruce J. Dezube MD David Aboulafia MD John Gerecitano MD PhD Ryan Sullivan MD Mary E. Cianfrocca DO David H. Henry MD Lee Ratner MD PhD Missak Haigentz Jr. MD Afshin Dowlati MD Richard F. Little MD Susan Percy Ivy MD John F. Deeken MD 《Cancer》2014,120(8):1194-1202
18.
Jorge J. Castillo MD Michael Furman MD Brady E. Beltrán MD Michele Bibas MD Mark Bower MD Weina Chen MD José L. Díez‐Martín MD Jane J. Liu MD Roberto N. Miranda MD Silvia Montoto MD Nahid M. Nanaji MD José‐Tomás Navarro MD Adam C. Seegmiller MD Julie M. Vose MD 《Cancer》2012,118(21):5270-5277
BACKGROUND:
Plasmablastic lymphoma (PBL) is a rare and aggressive B‐cell lymphoma strongly associated with human immunodeficiency virus (HIV) infection. The authors conducted a multi‐institutional, retrospective study to describe characteristics and determine prognostic factors in HIV‐associated PBL.METHODS:
For this study, the investigators included consecutive, HIV‐positive patients diagnosed between the years 2000 and 2010 whose tumors had a plasmablastic morphology, were cluster of differentiation 20 (CD20)‐negative, and expressed markers of plasmacytic differentiation.RESULTS:
Fifty patients from 13 institutions were evaluated. The median age was 43 years, and there was a male predominance. The median count of cells that were positive for CD4 (a glycoprotein expressed on the surface of T‐helper cells, monocytes, macrophages, and dendritic cells) was 206 cells/mm3. At presentation, 90% of patients had extranodal involvement, 69% presented with advanced stage disease, and 27% had oral involvement. Rearrangements of v‐myc myelocytomatosis viral oncogene homolog (MYC) were detected in 41% of the tested patients. Eighty‐five percent of patients received chemotherapy, with 63% receiving cyclophosphamide, doxorubicin, vincristine, and prednisone and 37% receiving more intensive regimens. The complete response (CR) rate was 66%. The median overall survival (OS) was 11 months regardless of the intensity of chemotherapy. In the survival analysis, an Eastern Cooperative Oncology Group performance status ≥2, advanced stage, and MYC rearrangements were associated significantly with a worse outcome, whereas attaining a CR with chemotherapy was associated with a better outcome.CONCLUSIONS:
The prognosis of PBL in HIV‐infected individuals remains poor in the highly active antiretroviral therapy era. Intensive chemotherapy regimens do not seem to increase survival in patients with HIV‐associated PBL. Cancer 2012. © 2012 American Cancer Society. 相似文献19.
Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus‐infected individuals in the United States
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Joseph E. Tota PhD Eric A. Engels MD MPH Margaret M. Madeleine PhD Christina A. Clarke PhD MPH Charles F. Lynch MD PhD Ana P. Ortiz PhD MPH Brenda Y. Hernandez PhD MPH Anil K. Chaturvedi PhD 《Cancer》2018,124(12):2515-2522
20.
Mitsuhisa Takatsuki Koji Natsuda Masaaki Hidaka Koji Sawada Motohiro Shindo Tomoyuki Endo Takeshi Hagiwara Hiroshi Yotsuyanagi Tomohiko Koibuchi Kunihisa Tsukada Haruka Uemura Kazuhiko Hayashi Tomoko Uehira Eiji Mita Masahiro Yamamoto Soichiro Takahama Susumu Eguchi 《Journal of gastrointestinal oncology.》2021,12(6):2952
BackgroundHuman immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection through unheated blood product for hemophilia caused in early 1980s has been significantly serious problem in Japan. After the development of HIV treatment in 1990s, HCV-related hepatocellular carcinoma (HCC) has been one of the most significant problem in these population. Treatment choices for HCC might be limited in hemophilia patients because of their bleeding tendency. The aim of this study was to elucidate the treatment choices and outcome of HCC in hemophilic patients coinfected with HIV/HCV due to contaminated blood products.MethodsWe asked 444 Japanese centers that specialize in treating HIV patients for participation, whether they have HIV/HCV coinfected cases with HCC, and the patient characteristics, treatments for HCC and survival after treatments were retrospectively reviewed according to each institutional medical records.ResultsOf 444 centers, 139 centers (31%) responded to the first query, and 8 centers (1.8%) ultimately provided 26 cases of HCC in coinfected hemophilic patients, diagnosed between December 1999 and December 2017. All 26 were male hemophilic patients, with a median age at HCC diagnosis of 49 (range, 34–73) years. Thirteen cases (50%) were HCV-RNA positive, and 14 cases (54%) had a solitary tumor. Even in the cases of Child-Pugh grade A, only 1 case underwent resection, and 18 cases (69%) did not receive the standard treatment recommended by the Japanese Society of Hepatology.ConclusionsHemophilic HCC patients with HIV/HCV coinfection may not routinely receive standard treatment due to their bleeding tendency and several complications related to HIV/HCV coinfection. 相似文献